August 18, 2017 10:07 AM EDT

Medivir out-licenses hep C drug to China’s Ascletis; Cellectis launches pioneering UCART123 US study

Shehla Shakoor

Managing Director

⇨ Ascletis has in-licensed the Chinese market rights for Stockholm-based Medivir’s NS5B inhibitor for hep C. Terms weren’t disclosed but Hangzhou-based Ascletis gets another …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Medivir out-licenses hep C drug to China’s Ascletis; Cellectis launches pioneering UCART123 US study

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Are programs with compounded GLP-1s safe for your population?

Medi­vir out-li­cens­es hep C drug to Chi­na’s As­cle­tis; Cel­lec­tis launch­es pi­o­neer­ing UCART123 US study

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Medivir out-licenses hep C drug to China’s Ascletis; Cellectis launches pioneering UCART123 US study

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Are programs with compounded GLP-1s safe for your population?